Shire has announced the recent FDA approval for its Adderall iteration, Mydayis. The drug, which was denied approval by the FDA nearly a decade ago, was finally approved this week following the inspection of 16 clinical studies. Both adults and children were included in the various studies. Shire is hoping to exceed $500b in sales to compete with Mydayis predecessor, Adderall, another Shire medication. Read the full press release here.